Literature DB >> 11157754

Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.

D Rotzer1, M Roth, M Lutz, D Lindemann, W Sebald, P Knaus.   

Abstract

Transforming growth factor-beta (TGF-beta) signals through membrane-bound serine/threonine kinase receptors, which upon stimulation phosphorylate Smad proteins and thereby trigger their nuclear translocation and transcriptional activity. Although the three mammalian isoforms of TGF-beta are highly homologous at the level of sequence, analysis of their in vivo function by gene knockouts revealed striking differences, suggesting no significant functional redundancy between TGF-beta1, -2 and -3. While signal transduction by TGF-beta1 has been well characterized, receptor binding and activation by the TGF-beta2 isoform is less well understood. Here, we show that TbetaRII-B, an alternatively spliced variant of the TGF-beta type II receptor, is a TGF-beta2 binding receptor, which mediates signalling via the Smad pathway in the absence of any TGF-beta type III receptor (TbetaRIII). L6 cells lacking endogenous TbetaRIII as well as TbetaRII-B do not respond to TGF-beta2. Transfection of these cells with TbetaRII-B restores TGF-beta2 sensitivity. The expression of TbetaRII-B is restricted to cells originating from tissues such as bone where the isoform TGF-beta2 has a predominant role. This reflects the importance of this receptor in TGF-beta isoform-specific signalling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157754      PMCID: PMC133482          DOI: 10.1093/emboj/20.3.480

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  59 in total

1.  Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells.

Authors:  A Ishisaki; K Yamato; S Hashimoto; A Nakao; K Tamaki; K Nonaka; P ten Dijke; H Sugino; T Nishihara
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

2.  GH3 pituitary tumor cells contain heteromeric type I and type II receptor complexes for transforming growth factor beta and activin-A.

Authors:  A Moustakas; T Takumi; H Y Lin; H F Lodish
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

3.  Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart.

Authors:  C B Brown; A S Boyer; R B Runyan; J V Barnett
Journal:  Science       Date:  1999-03-26       Impact factor: 47.728

4.  Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I/Type II receptor complex in live cells.

Authors:  R G Wells; L Gilboa; Y Sun; X Liu; Y I Henis; H F Lodish
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

5.  Purification and characterization of transforming growth factor-beta 2.3 and -beta 1.2 heterodimers from bovine bone.

Authors:  Y Ogawa; D K Schmidt; J R Dasch; R J Chang; C B Glaser
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

Review 6.  TGF-beta signal transduction.

Authors:  J Massagué
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

7.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.

Authors:  J J Yin; K Selander; J M Chirgwin; M Dallas; B G Grubbs; R Wieser; J Massagué; G R Mundy; T A Guise
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

8.  Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated.

Authors:  R J Diebold; M J Eis; M Yin; I Ormsby; G P Boivin; B J Darrow; J E Saffitz; T Doetschman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

9.  Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass.

Authors:  E Filvaroff; A Erlebacher; J Ye; S E Gitelman; J Lotz; M Heillman; R Derynck
Journal:  Development       Date:  1999-10       Impact factor: 6.868

10.  Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane.

Authors:  L Gilboa; R G Wells; H F Lodish; Y I Henis
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

View more
  26 in total

1.  Expression of heterogeneous nuclear ribonucleoproteins A2 and b1 in the thyroid follicular cells.

Authors:  Yukiko Yano; Wenwen Wu; Hiroshi Kamma; Masachika Fujiwara; Hisato Hara; Tohru Yashiro; Ei Ueno; Masanao Miwa; Yuji Aiyoshi
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 2.  TGF-β Family Signaling in Mesenchymal Differentiation.

Authors:  Ingo Grafe; Stefanie Alexander; Jonathan R Peterson; Taylor Nicholas Snider; Benjamin Levi; Brendan Lee; Yuji Mishina
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

3.  The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease γ-secretase.

Authors:  Cheyne R Blair; Jacqueline B Stone; Rebecca G Wells
Journal:  Biochim Biophys Acta       Date:  2010-12-15

4.  TGFβRIIb mutations trigger aortic aneurysm pathogenesis by altering transforming growth factor β2 signal transduction.

Authors:  Katharine J Bee; David C Wilkes; Richard B Devereux; Craig T Basson; Cathy J Hatcher
Journal:  Circ Cardiovasc Genet       Date:  2012-10-24

5.  TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.

Authors:  Neriya Gutgold; Ben Davidson; Liora Jacobs Catane; Arild Holth; Ellen Hellesylt; Claes G Tropé; Anne Dørum; Reuven Reich
Journal:  Virchows Arch       Date:  2017-04-21       Impact factor: 4.064

Review 6.  Targeting the transforming growth factor-beta signaling pathway in human cancer.

Authors:  Nagathihalli S Nagaraj; Pran K Datta
Journal:  Expert Opin Investig Drugs       Date:  2010-01       Impact factor: 6.206

7.  The Drosophila Activin-like ligand Dawdle signals preferentially through one isoform of the Type-I receptor Baboon.

Authors:  Philip A Jensen; Xiaoyan Zheng; Tzumin Lee; Michael B O'Connor
Journal:  Mech Dev       Date:  2009-09-18       Impact factor: 1.882

8.  Heart and liver defects and reduced transforming growth factor beta2 sensitivity in transforming growth factor beta type III receptor-deficient embryos.

Authors:  Kaye L Stenvers; Melinda L Tursky; Kenneth W Harder; Nicole Kountouri; Supavadee Amatayakul-Chantler; Dianne Grail; Clayton Small; Robert A Weinberg; Andrew M Sizeland; Hong-Jian Zhu
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

Review 9.  Transforming growth factor beta in cardiovascular development and function.

Authors:  Mohamad Azhar; Jo El J Schultz; Ingrid Grupp; Gerald W Dorn; Pierre Meneton; Daniel G M Molin; Adriana C Gittenberger-de Groot; Thomas Doetschman
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

10.  Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung.

Authors:  Namasivayam Ambalavanan; Teodora Nicola; James Hagood; Arlene Bulger; Rosa Serra; Joanne Murphy-Ullrich; Suzanne Oparil; Yiu-Fai Chen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-16       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.